Curis, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2000-01-01
- Employees
- 49
- Market Cap
- $35.9M
- Website
- http://www.curis.com
Clinical Trials
21
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (20 trials with phase data)• Click on a phase to view related trials
Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04475523
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of Orally Administered CA-4948(IRAK4i) as a Monotherapy in patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- Conditions
- Acute Myelogenous Leukemia (AML) or higher-risk Myelodysplastic Syndrome (MDS).
- Interventions
- Drug: EmavusertibDrug: Venetoclax
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Curis Inc.
- Target Recruit Count
- 70
- Registration Number
- 2024-513313-13-00
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Conditions
- Relapsed Primary Central Nervous System LymphomaRelapsed Hematologic MalignancyRefractory Primary Central Nervous System LymphomaRefractory Hematologic Malignancy
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT03328078
- Locations
- 🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸City of Hope, Duarte, California, United States
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT02812875
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations
- Conditions
- Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations
- Interventions
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT02674750
- Locations
- 🇺🇸
University of California San Francisco-Fresno, Fresno, California, United States
🇺🇸University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
- Prev
- 1
- 2
- 3
- Next